阳普医疗(300030) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥177,119,317.52, representing a 2.13% increase year-over-year, while the year-to-date revenue decreased by 10.19% to ¥529,552,805.76[3] - The net profit attributable to shareholders for Q3 2022 was -¥21,836,610.48, a decline of 60.81% compared to the same period last year, and a significant drop of 269.58% year-to-date to -¥57,801,791.57[3] - The basic and diluted earnings per share for Q3 2022 were both -¥0.07, reflecting a decrease of 61.11% year-over-year, with year-to-date figures at -¥0.19, down 272.73%[3] - Total operating revenue for Q3 2022 was CNY 529.55 million, a decrease of 10.21% from CNY 589.66 million in the same period last year[32] - Net profit for Q3 2022 was a loss of CNY 55.55 million, compared to a profit of CNY 34.26 million in Q3 2021, indicating a significant decline[34] - The total comprehensive income for Q3 2022 was a loss of CNY 55.61 million, contrasting with a gain of CNY 34.23 million in Q3 2021[34] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,663,439,497.98, down 8.86% from the end of the previous year[3] - The company's total liabilities decreased to CNY 700.06 million from CNY 794.63 million, a reduction of 11.88% year-over-year[32] - The total equity attributable to shareholders decreased to CNY 929.85 million from CNY 1,000.19 million, a decline of 7.06%[32] - The company's current assets decreased to RMB 725,944,318.76 from RMB 843,942,487.10 at the beginning of the year[30] - The company's inventory increased slightly to RMB 154,391,904.37 from RMB 151,658,119.65 at the beginning of the year[30] - Long-term equity investments decreased to RMB 130,874,653.32 from RMB 183,597,011.19 at the beginning of the year[30] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥20,987,651.27, a significant decrease of 85.24%[3] - Operating cash inflow for the period was CNY 646,958,382.43, down 22.7% from CNY 836,461,723.90 in the previous period[35] - Net cash flow from operating activities decreased to CNY 20,987,651.27, a decline of 85.2% compared to CNY 142,213,101.06 in the same period last year[35] - Cash outflow from investing activities totaled CNY 225,267,837.24, significantly reduced from CNY 557,284,040.78 in the previous period[35] - Net cash flow from investing activities was -CNY 71,660,746.85, worsening from -CNY 53,367,511.51 year-over-year[35] - Net cash flow from financing activities decreased to -CNY 96,097,349.63, compared to -CNY 45,169,235.82 in the same period last year[36] Business Segments - The revenue from the main business, vacuum blood collection systems, increased by 5.61% year-over-year to ¥281,797,000, while revenue from the microbiological transport system decreased by 68.08% to ¥41,533,000[6] - The company plans to focus on the steady growth of its main business and address the challenges faced in the microbiological transport system segment[6] Investments and Acquisitions - The company reported a significant decline in investment income, with a loss of ¥53,169,230.40 for the year-to-date period, compared to a gain of ¥3,471,103.67 in the previous year[12] - The company completed the acquisition of 100% equity of its subsidiary Yangpu Smart Medical Technology from Guangzhou Huqiao, receiving a total payment of RMB 41,639.44[26] - The company established the Zhuhai Gejin Yangpu Health Industry Fund with an investment of RMB 25 million, completing registration and private fund filing during the reporting period[24] Shareholder Information - The total number of common shareholders at the end of the reporting period was 31,105, with no preferred shareholders[17] - The largest shareholder, Deng Guanhua, holds 17.55% of shares, totaling 54,268,555 shares, with 40,701,416 shares pledged[17] Research and Development - The company launched the Impro224 vacuum blood collection tube performance verification system, enhancing automation in performance validation and data processing[21] - The research on ImproGene® cfDNA tubes was published in a prominent journal, demonstrating superior performance for ctDNA sample collection and preservation[22] - Research and development expenses increased to CNY 30.67 million, up from CNY 27.54 million, representing an increase of 7.73%[32] Legal and Regulatory - Shenzhen Xirun Financing Leasing Co., Ltd. is involved in a lawsuit with a claim amount of RMB 6.2946 million, with a favorable ruling for Shenzhen Xirun[28] - The company changed its accounting firm to Rongcheng Accounting Firm for the 2022 audit, with the appointment lasting one year[27] Foreign Exchange and Financial Expenses - The company reported a foreign exchange gain of CNY 1,457,167.69, a significant increase compared to a loss of CNY -371,730.20 in the previous period[15] - The financial expenses decreased by 49.84% to ¥9,284,890.26 due to the repayment of company bonds and lower financing costs[12]